Cytotoxic Properties of Adamantyl Isothiocyanate and Potential In vivo Metabolite Adamantyl‐N‐Acetylcystein in Gynecological Cancer Cells
Open Access
- 4 October 2011
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 79 (1) , 92-103
Abstract
This study determined the in vitro potential of novel compounds adamantyl‐N‐acetylcystein and adamantyl isothiocyanate to treat gynecological cancers. Adamantyl‐N‐acetylcystein is postulated to be an in vivo metabolite of adamantyl isothiocyanate as dietary isothiocyanates are converted to N‐acetylcysteine‐conjugates. A viability assay suggested that adamantyl isothiocyanate and adamantyl‐N‐acetylcystein are cytotoxic to cancer cells including gynecological cell lines. A NCI60 cancer cell assay revealed that growth‐inhibition and cytotoxicity of adamantyl‐N‐acetylcystein were cell line, but not tissue type‐specific. Cell cycle studies revealed that adamantyl‐N‐acetylcystein and adamantyl isothiocyanate arrest SKOV‐3 ovarian cancer cells in G2/M phase. By TUNEL, immunoblotting, and viability studies employing caspase and p38 mitogen‐activated protein kinase inhibitors, we proved that reduction in SKOV‐3 viability is a consequence of DNA fragmentation and apoptosis. Cytotoxic action of adamantyl‐N‐acetylcystein in SKOV‐3 and endometrial cancer (ECC‐1, RL95‐2, AN3CA, and KLE) cells required excess generation of reactive oxygen species which could be blocked by antioxidant co‐treatment. Adamantyl‐N‐acetylcystein treatment led to modified expression or activation of apoptotic and oncogenic proteins such as JNK/SAPK, AKT, XIAP, and EGF‐R for SKOV‐3 and JNK/SAPK and ERK1/2 for ECC‐1 cells. We suggest the further development of adamantyl‐N‐acetylcystein by sensitizing cells to the drug using signaling inhibitors or redox‐modulating agents and by evaluating the drug efficacy in ovarian and endometrial in‐vivo tumor models.Keywords
This publication has 53 references indexed in Scilit:
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cellsBritish Journal of Cancer, 2008
- Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusGynecologic Oncology, 2008
- A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cellsGynecologic Oncology, 2008
- Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplicationGenes & Development, 2007
- Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell linesBioorganic & Medicinal Chemistry Letters, 2007
- Anti‐proliferative and Pro‐apoptotic Properties of 3‐Bromoacetoxy Calcidiol in High‐risk NeuroblastomaChemical Biology & Drug Design, 2007
- An Adamantyl-Substituted Retinoid-Derived Molecule That Inhibits Cancer Cell Growth and Angiogenesis by Inducing Apoptosis and Binds to Small Heterodimer Partner Nuclear Receptor: Effects of Modifying Its Carboxylate Group on Apoptosis, Proliferation, and Protein-Tyrosine Phosphatase ActivityJournal of Medicinal Chemistry, 2007
- Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterationsBritish Journal of Cancer, 2006
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996